Interventional Oncology http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology <h1 class="header1">Interventional Oncology News</h1> en BIBA Medical Ltd Fri, 18 Apr 2014 09:21:26 GMT http://blogs.law.harvard.edu/tech/rss 3360 Affino 5 RSS Generator webeditor@bibamedical.com COSY trial shows highly reduced radioembolization procedure time and radiation dose http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/cosy-trial-shows-highly-reduced-radioembolization-procedure-time-and-radiation-dose <div style="display:block;"> <div id="ImageThumb1" style="float:left;"><a href="http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/cosy-trial-shows-highly-reduced-radioembolization-procedure-time-and-radiation-dose"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/029/surefire_catheter_thumb.jpg" border="0" hspace="5" vspace="5" /></a></div> <div id="ItemTeaser1" style="float:left;"> Surefire Medical has announced that the COSY clinical trial (Coiling vs. Surefire infusion system in Y90) showed significant reductions in fluoroscopy time, procedure time, radiation dose and contrast dose when using the Surefire Infusion System without coiling. </div> </div> Fri, 28 Mar 2014 10:24:00 +0000 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/cosy-trial-shows-highly-reduced-radioembolization-procedure-time-and-radiation-dose Sirtex and Guerbet announce collaboration in clinical studies in liver cancer http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sirtex-and-guerbet-announce-collaboration-in-clinical-studies-in-liver-cancer <div style="display:block;"> <div id="ItemTeaser2" style="float:left;"> Sirtex and Guerbet have announced that the two companies are entering into a collaboration to advance research in primary and secondary metastatic liver cancer. </div> </div> Thu, 27 Mar 2014 11:36:00 +0000 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sirtex-and-guerbet-announce-collaboration-in-clinical-studies-in-liver-cancer Cancer specialists to head to Berlin to attend ECIO http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/cancer-specialists-to-head-to-berlin-to-attend-ecio- <div style="display:block;"> <div id="ItemTeaser3" style="float:left;"> The world’s leading radiologists, oncologists and surgeons will head to Germany in April for the European Conference on International Oncology (ECIO, 23-26 April, Berlin, Germany). </div> </div> Thu, 27 Mar 2014 10:55:00 +0000 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/cancer-specialists-to-head-to-berlin-to-attend-ecio- Radioembolization offers new, safe treatment for metastatic breast cancer http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/radioembolization-offers-new-safe-treatment-for-metastatic-breast-cancer <div style="display:block;"> <div id="ImageThumb4" style="float:left;"><a href="http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/radioembolization-offers-new-safe-treatment-for-metastatic-breast-cancer"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/020/Robert-Lewandowski_thumb.jpg" border="0" hspace="5" vspace="5" /></a></div> <div id="ItemTeaser4" style="float:left;"> The largest study of its kind to date shows that minimally invasive radioembolization may slow metastatic disease progression in liver when no other treatment options remain, according to research being presented at the Society of Interventional Radiology’s 39th Annual Scientific Meeting (22–27 March, San Diego, USA). </div> </div> Mon, 24 Mar 2014 16:10:00 +0000 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/radioembolization-offers-new-safe-treatment-for-metastatic-breast-cancer Safety and efficacy of percutaneous cryoablation in renal cell carcinoma in 2014 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/safety-and-efficacy-of-percutaneous-cryoablation-in-renal-cell-carcinoma-in-2014- <div style="display:block;"> <div id="ImageThumb5" style="float:left;"><a href="http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/safety-and-efficacy-of-percutaneous-cryoablation-in-renal-cell-carcinoma-in-2014-"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/034/thumb_Christos-Georgiades_Thumb.jpg" border="0" hspace="5" vspace="5" /></a></div> <div id="ItemTeaser5" style="float:left;"> The outcomes from our study on the efficacy and safety of percutaneous cryoablation, published recently in CardioVascular and Interventional Radiology (CVIR), are the result of the most rigorous investigation on the subject to-date. These exceptional numbers, however, are a double-edged sword. On one hand, they approach those of the gold standard, on the other, we must prove they are widely reproducible, writes Christos Georgiades </div> </div> Thu, 27 Feb 2014 10:21:00 +0000 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/safety-and-efficacy-of-percutaneous-cryoablation-in-renal-cell-carcinoma-in-2014-